Study of Photodynamic Therapy (PDT) Using HPPH in Barrett's Esophagus

Completed · Phase 1

Conditions studied: Barrett's Esophagus, CIS, High Grade Dysplasia

In brief

A Study to identify toxicity and optimal photodynamic treatment parameters using the photosensitizer 2-\[1-hydroxyethyl\]-2-devinylpyropheophorbide-a (HPPH) in high grade dysplasia, carcinoma-in-situ, or early adenocarcinoma in Barrett's esophagus.

Key facts

Study ID

NCT01236443

Run by

Roswell Park Cancer Institute

People needed

18

Starts

2000-08-01

Expected to finish

2013-04-01

Last updated by the study team

2014-01-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient must have biopsy proven high-grade (severe) dysplasia, carcinoma-in-situ or early stage adenocarcinoma;
• Patient may have received prior therapy; e.g. Nd-YAG laser, radiation therapy or chemotherapy. At least one month must have elapsed between prior treatments and PDT.
• Tumors can be primary or recurrent, Stage 0 or I, N0M (any).
• Patients must have no contraindications to endoscopy.
• Male or female patients must be 18 years old or older. Female patients must not be pregnant and must be practicing a medically acceptable form of birth control or be sterile or post-menopausal. A pregnancy test is required and must be negative.
• Patients must sign an Informed Consent according to FDA guidelines and be acceptable to the RPCI IRB.
• Patients must have a Karnofsky status 50 or above.
• Operable patients are not excluded.

You may not qualify if…

• Patients with tumors of grade greater than T-1.
• Porphyria or hypersensitivity to porphyrin or porphyrin-like compounds.
• WBC <2,000; platelet count <50,000, prothrombin time 1.5 times above the upper normal limit.
• Patients with impaired renal and/or hepatic function (total serum bilirubin >3.0 mg/d, serum creatinine >3 mg%, alkaline phosphatase (hepatic) or SGOT >3 times the upper normal limit.
• Patients on concurrent chemotherapy or radiation therapy will be excluded as well as those having received prior treatment for the esophageal cancer within 4 weeks of enrollment.
• If the patient has cancer other than non-melanoma skin cancer they must be deemed disease free by their treating physician.

Where it is running

• Roswell Park cancer institute — Buffalo, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.